The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Restricting the Selection of Antibiotic‐Resistant Mutants: A General Strategy Derived from Fluoroquinolone Studies
Abstract
Studies with fluoroquinolones have led to a general method for restricting the selection of antibiotic-resistant mutants. The strategy is based on the use of antibiotic concentrations that require cells to obtain 2 concurrent resistance mutations for growth. That concentration has been called the "mutant prevention concentration" (MPC) because no resistant colony is recovered even when >10(10) cells are plated. Resistant mutants are selected exclusively within a concentration range (mutant selection window) that extends from the point where growth inhibition begins, approximated by the minimal inhibitory concentration, up to the MPC. The dimensions of the mutant selection window can be reduced in a variety of ways, including adjustment of antibiotic structure and dosage regimens. The window can be closed to prevent mutant selection through combination therapy with > or =2 antimicrobial agents if their normalized pharmacokinetic profiles superimpose at concentrations that inhibit growth. Application of these principles could drastically restrict the selection of drug-resistant pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA gyrase, topoisomerase IV, and the 4-quinolones.
Drlica, K., & Zhao, X. (1997) · Microbiology and molecular biology reviews : MMBR · doi:10.1128/.61.3.377-392.1997 · Cited by 1,494
Self-citationThe Emergence of Drug-Resistant Tuberculosis in New York City
Frieden, T. R., Sterling, T., Pablos-Mendez, A., Kilburn, J. O., Cauthen, G. M., & Dooley, S. W. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280801 · Cited by 939
Quinolone-Resistant Campylobacter jejuni Infections in Minnesota, 1992–1998
Smith, K. E., Besser, J. M., Hedberg, C. W., Leano, F. T., Bender, J. B., Wicklund, J. H., Johnson, B. P., Moore, K. A., & Osterholm, M. T. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905203402001 · Cited by 666
Staphylococcus aureus: A Well–Armed Pathogen
Archer, G. L. (1998) · Clinical Infectious Diseases · doi:10.1086/520289 · Cited by 658
Endtz, H. P., Ruijs, G. J., van Klingeren, B., Jansen, W. H., van der Reyden, T., & Mouton, R. P. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/27.2.199 · Cited by 590
Bifani, P. J. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530300036037 · Cited by 381
Emergence and Dissemination of Quinolone-Resistant Escherichia coli in the Community
Garau, J., Xercavins, M., Rodríguez-Carballeira, M., Gómez-Vera, J. R., Coll, I., Vidal, D., Llovet, T., & Ruíz-Bremón, A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2736 · Cited by 337
Mechanism of fluoroquinolone action
Drlica, K. (1999) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(99)00008-9 · Cited by 319
Self-citationBlondeau, J. M., Zhao, X., Hansen, G., & Drlica, K. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.433-438.2001 · Cited by 314
Self-citationVernon, A., Burman, W., Benator, D., Khan, A., & Bozeman, L. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11467-8 · Cited by 308
Cited by
Microbiological effects of sublethal levels of antibiotics
Andersson, D. I., & Hughes, D. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3270 · Cited by 1,757
Antibacterial free fatty acids: activities, mechanisms of action and biotechnological potential
Desbois, A. P., & Smith, V. J. (2010) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-009-2355-3 · Cited by 1,442
Mechanisms of Resistance to Quinolones
Jacoby, G. A. (2005) · Clinical Infectious Diseases · doi:10.1086/428052 · Cited by 924
Efflux-Mediated Drug Resistance in Bacteria
Li, X.-Z., & Nikaido, H. (2004) · Drugs · doi:10.2165/00003495-200464020-00004 · Cited by 798
Strategies to Minimize Antibiotic Resistance
Lee, C.-R., Cho, I., Jeong, B., & Lee, S. (2013) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph10094274 · Cited by 446
The mutant selection window and antimicrobial resistance
Drlica, K. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg269 · Cited by 437
Self-citationFluoroquinolones, tuberculosis, and resistance
Ginsburg, A. S., Grosset, J. H., & Bishai, W. R. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00671-6 · Cited by 403
The pharmacokinetic–pharmacodynamic approach to a rational dosage regimen for antibiotics
Toutain, P. L., del Castillo, J. R. E., & Bousquet-Mélou, A. (2002) · Research in Veterinary Science · doi:10.1016/s0034-5288(02)00039-5 · Cited by 384
Mutant Selection Window Hypothesis Updated
Drlica, K., & Zhao, X. (2007) · Clinical Infectious Diseases · doi:10.1086/511642 · Cited by 383
Self-citationQuinolones: Action and Resistance Updated
Drlica, K., Hiasa, H., Kerns, R., Malik, M., Mustaev, A., & Zhao, X. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789630947 · Cited by 376
Self-citationVan Bambeke, F., Michot, J.-M., Van Eldere, J., & Tulkens, P. M. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01131.x · Cited by 342
Antibiotic resistance—What’s dosing got to do with it?
Roberts, J. A., Kruger, P., Paterson, D. L., & Lipman, J. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e318180fe62 · Cited by 339
Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs
Nielsen, E. I., & Friberg, L. E. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005769 · Cited by 332
Managing skin and soft tissue infections: expert panel recommendations on key decision points
Eron, L. J. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg466 · Cited by 319
Fluoroquinolones: Action and Resistance
Drlica, K., & Malik, M. (2003) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026033452537 · Cited by 317
Self-citationBlondeau, J. M., Zhao, X., Hansen, G., & Drlica, K. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.433-438.2001 · Cited by 314
Self-citationMulti-targeting by monotherapeutic antibacterials
Silver, L. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2202 · Cited by 311
Mechanisms of quinolone action and microbial response
Hawkey, P. M. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg207 · Cited by 288
Zhao, Y., Prideaux, B., Nagasaki, Y., Lee, M. H., Chen, P.-Y., Blanc, L., Ho, H., Clancy, C. J., Nguyen, M. H., Dartois, V., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-17 · Cited by 102
CD101: a novel long-acting echinocandin
Zhao, Y., Perez, W. B., Jiménez‐Ortigosa, C., Hough, G., Locke, J. B., Ong, V., Bartizal, K., & Perlin, D. S. (2016) · Cellular Microbiology · doi:10.1111/cmi.12640 · Cited by 81
Metadata
- Authors
- Zhao, X., & Drlica, K.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-09-15
- Volume
- 33
- Issue
- s3
- Pages
- S147-S156
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2128160648
- Cited by
- 397
- References
- 30
- FWCI
- 9.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.